Stock APRICUS BIOSCIENCES INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News Apricus Biosciences Inc Nasdaq

Equities

US03832V1098

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for Apricus Biosciences Inc
05-16 Seelos Therapeutics, Inc. announced that it expects to receive $1.137029 million in funding CI
05-14 Seelos Therapeutics to Implement Reverse Stock Split to Regain Bourse Compliance MT

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Seelos Therapeutics Announces Pricing of $1.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
PR
Reverse Split: 1 of 8
FA
Seelos Therapeutics, Inc. announced that it expects to receive $1.137029 million in funding
CI
Seelos Therapeutics to Implement Reverse Stock Split to Regain Bourse Compliance
MT
Seelos Therapeutics Announces 1-for-8 Reverse Stock Split
PR
Seelos: Q1 Earnings Snapshot
AQ
Seelos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Seelos Therapeutics, Inc. Announces Resignation of Daniel J. O?Connor from the Board
CI
Seelos Therapeutics Announces Strategic Focus on Mental Health Initiatives and Provides an Update on Current Discussions of Potential Partnerships and Collaborations
PR
Seelos Therapeutics, Inc. Announces Appointment of Richard Pascoe as Chairman of the Board of Directors
CI
Wall Street Set to Open Lower Ahead of Two-Day Fed Meeting; Housing Starts Surge Higher Than Expected
MT
Seelos Therapeutics' ALS treatment fails in mid-stage study
RE
Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose)
PR
Seelos Therapeutics, Inc. Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis Study with SLS-005 (IV Trehalose)
CI
Seelos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Singapore Stocks Open on Monday in Red; IX Biopharma’s Stock Plunge 9% Following Contract Termination
MT
IX Biopharma’s Subsidiary Issues Termination Notice for Licensing Agreement; Shares Plunge 9%
MT
Seelos Therapeutics, Inc. Announces $4.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
AQ
Seelos Therapeutics Launches Registered Direct Offering, Concurrent Private Placement
MT
Seelos Therapeutics, Inc. Announces $4.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SEEL Stock
  4. Stock
  5. News Apricus Biosciences Inc